FDA Brief

Warning letters Drugs

FDA warning letter to

Azurity Pharmaceuticals, Inc.

High riskIssued Sep 20, 2024Posted Sep 24, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.

What happened

FDA inspected Azurity's drug manufacturing facility at 841 Woburn Street, Wilmington, MA, from February 2 to March 2, 2023, and reviewed the firm's website. FDA found the FIRST Unit-of-Use Kits were unapproved new drugs because they lacked FDA-approved applications, and found current good manufacturing practice (CGMP) violations in complaint investigations and stability testing. The complaint issues included about 86 crystallization complaints and a lead complaint where FDA said the firm investigated only one of two batches and did no lead testing.

What FDA found

  1. The company introduced FIRST Unit-of-Use Kits as new drugs without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  2. The quality unit did not thoroughly investigate unexplained discrepancies, including about 86 crystallization complaints and a lead complaint without lead testing.

    21 CFR 211.192
  3. The company did not adequately assess stability test results, including unknown impurity out-of-specification results, to set storage conditions and expiration dates.

    21 CFR 211.166(a)
  4. FDA deemed the drug products adulterated because manufacturing methods, facilities, or controls did not meet CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells Azurity to immediately discontinue marketing all unapproved prescription drugs made at the facility and correct the cited violations. The firm must respond in writing within 15 working days with corrective steps and documentation, and FDA recommends engaging a qualified CGMP consultant.

Who should pay attention

  • pharmacies and clinicians who dispense or prescribe FIRST kits
  • brands or distributors sourcing drugs from Azurity or similar manufacturers
  • quality teams managing complaint investigations and stability programs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk